Wexford Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Wexford Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-79,492	Closed	-$1.44M	–	328
2016 Q3	$1.44M	Buy	+79,492	New	+$1.55M	0.24%	86
2015 Q4	–	Sell	-99,719	Closed	-$1.98M	–	99
2015 Q3	$1.98M	Buy	+99,719	New	+$3.15M	0.38%	55
2014 Q2	–	Sell	-283,777	Closed	-$4.29M	–	191
2014 Q1	$4.29M	Buy	+283,777	New	+$3.2M	0.33%	48

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wexford Capital's HZNP Position: Q4 2016 in Review

Wexford Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2016, closing a stake of 79,492 shares — an estimated $1.44M sold.

Wexford Capital first reported a position in HZNP in Q1 2014 and held it in 3 quarters. The position peaked at $4.29M in Q1 2014. 234 funds tracked by Wall St. Rank hold HZNP as of Q4 2016.

Wexford Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2016 after selling out during the quarter.
Wexford Capital sold 79,492 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2016, an estimated $1.44M.
Wexford Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2014 and held it in 3 quarters.
Wexford Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $4.29M in Q1 2014.
234 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2016.

Based on Wexford Capital's 13F filing for Q4 2016, filed 14 Feb 2017.